Pharmacokinetics of sepantronium bromide (YM155), a small-molecule suppressor of survivin, in Japanese patients with advanced solid tumors: dose proportionality and influence of renal impairment
Cancer Chemotherapy and Pharmacology, 08/08/2012
Aoyama Y et al. – While age and sex did not significantly affect the pharmacokinetics (PK) of sepantronium, moderate renal impairment increased exposure of sepantronium by about 30 %. The results suggest that no dose adjustment is required for patients with mild renal impairment.